Author

Matthew Ho

Institutions: Hospital of the University of Pennsylvania, Abramson Cancer Center, University of Pennsylvania

Observed institutions: Hospital of the University of Pennsylvania, Abramson Cancer Center, University of Pennsylvania

ORCID: 0000-0001-7937-1557

Observed ORCID: 0000-0001-7937-1557

OpenAlex ID: A5136271972

CART-immune-related adverse events after BCMA CAR-T therapy

2026 · Luca Paruzzo, Matthew Ho, et al. · Molecular Therapy Oncology · 2

Decade-long persistence of CD19 CAR T cells in B cell lymphomas

2026 · Luca Paruzzo, Emeline R. Chong, et al. · Nature Medicine · 1

Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy

2026 · Michael Schneider, Luca Paruzzo, et al. · Nature Communications · 1

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

2026 · Luca Paruzzo, Emeline R. Chong, et al. · Nature Medicine

T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia

2026 · Julia Han Noll, Devin Dersh, et al. · Blood

A modular γδ TCR-T platform combining KRAS pMHC targeting with re-dosable mRNA engager redirection

2026 · Ángel Ramírez-Fernández, Adham S. Bear, et al. · Journal of Hematology & Oncology

Works count: 6

Citation count: 4

H-index: 1

I10-index: